KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-Current Deferred Tax Liability: 2017-2018

Historic Non-Current Deferred Tax Liability for Amneal Pharmaceuticals (AMRX) over the last 2 years, with Dec 2018 value amounting to $1.2 million.

  • Amneal Pharmaceuticals' Non-Current Deferred Tax Liability fell 64.16% to $1.2 million in Q4 2018 from the same period last year, while for Dec 2018 it was $1.2 million, marking a year-over-year decrease of 64.16%. This contributed to the annual value of $1.2 million for FY2018, which is 64.16% down from last year.
  • As of FY2018, Amneal Pharmaceuticals' Non-Current Deferred Tax Liability stood at $1.2 million, which was down 64.16% from $3.3 million recorded in FY2017.
  • Over the past 5 years, Amneal Pharmaceuticals' Non-Current Deferred Tax Liability peaked at $3.3 million during FY2017, and registered a low of $1.2 million during FY2018.
  • Over the past 2 years, Amneal Pharmaceuticals' median Non-Current Deferred Tax Liability value was $2.2 million (recorded in 2017), while the average stood at $2.2 million.
  • Data for Amneal Pharmaceuticals' Non-Current Deferred Tax Liability shows a maximum YoY plummeted of 64.16% (in 2018) over the last 5 years.
  • Yearly analysis of 2 years shows Amneal Pharmaceuticals' Non-Current Deferred Tax Liability stood at $3.3 million in 2017, then tumbled by 64.16% to $1.2 million in 2018.